by Peter A. McCullough
August 25, 2023
from PeterMcCulloughMd Website
Information sent by MGG
for Those Suffering from Long-COVID
and Post-Acute Sequelae
I checked clinicaltrials.gov and no such trials have been planned.
The Biden HHS US Action Plan for Long-COVID Research has pumped a billion dollars into long-COVID research and no new therapies have emerged.
At three and one half years into the 'pandemic' and two and a half years into the COVID-19 vaccine debacle, myself and my clinic partners formulated a baseline regimen upon which additional drugs or agents can be added.
We believe the
Spike protein and the inflammation
cause by it and its proteolytic fragments are at the heart of the
pathophysiology we are observing.
We found two compounds, nattokinase and bromelain.
Curcumin was added for its anti-inflammatory properties in the setting of post-COVID and vaccine patients.
The main safety caveats
are bleeding and allergic reactions, both of which are manageable.
It is our experience that both nattokinase and bromelain can be used
in addition to antiplatelet and anticoagulant drugs with physician
McCullough PA, Wynn C, Procter BC.
Journal of American Physicians and Surgeons
Volume 28 Number 3 Fall 2023, 90-93.
While we are seeing case examples of improvement, we aim to collaborate with others as we did with the McCullough Protocol, to demonstrate,